Description

Mustang Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to transforming groundbreaking advancements in cell and gene therapies into potential therapeutic options for hematological malignancies, solid tumors, and uncommon genetic conditions. Its research and development efforts are primarily directed towards gene therapy programs for rare genetic disorders and chimeric antigen receptor (CAR) T-cell treatments for both blood cancers and various solid tumors. Among its lead gene therapy candidates are MB-107 and MB-207, designed to address X-linked severe combined immunodeficiency. This is a severe, rare genetic immune disorder where affected infants typically do not survive beyond their first year without medical intervention. In the sphere of CAR T-cell therapies for blood-related cancers, Mustang Bio is advancing several programs: MB-102 targets blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 focuses on B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia; and MB-104 is under development for multiple myeloma and light chain amyloidosis. For solid tumor indications, their CAR T-cell pipeline includes MB-101 for glioblastoma; MB-103 for glioblastoma multiforme and metastatic breast cancer that has spread to the brain; and MB-105 for prostate and pancreatic cancers. The company also features MB-108, a novel oncolytic herpes simplex virus, in its portfolio. To support its endeavors, Mustang Bio has established license agreements with key organizations such as Nationwide Children's Hospital, CSL Behring, Mayo Clinic, Leiden University Medical Centre, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. Established in 2015, Mustang Bio, Inc. maintains its corporate headquarters in Worcester, Massachusetts.